全文获取类型
收费全文 | 257569篇 |
免费 | 10874篇 |
国内免费 | 2826篇 |
专业分类
耳鼻咽喉 | 2105篇 |
儿科学 | 9193篇 |
妇产科学 | 4282篇 |
基础医学 | 25343篇 |
口腔科学 | 5967篇 |
临床医学 | 27037篇 |
内科学 | 42657篇 |
皮肤病学 | 3851篇 |
神经病学 | 11411篇 |
特种医学 | 4651篇 |
外国民族医学 | 2篇 |
外科学 | 35895篇 |
综合类 | 24162篇 |
现状与发展 | 10篇 |
一般理论 | 7篇 |
预防医学 | 31379篇 |
眼科学 | 3777篇 |
药学 | 25190篇 |
170篇 | |
中国医学 | 7616篇 |
肿瘤学 | 6564篇 |
出版年
2023年 | 2229篇 |
2022年 | 3550篇 |
2021年 | 6689篇 |
2020年 | 6159篇 |
2019年 | 16877篇 |
2018年 | 16082篇 |
2017年 | 8959篇 |
2016年 | 4566篇 |
2015年 | 4739篇 |
2014年 | 10100篇 |
2013年 | 11728篇 |
2012年 | 9365篇 |
2011年 | 9446篇 |
2010年 | 7555篇 |
2009年 | 6896篇 |
2008年 | 7135篇 |
2007年 | 7946篇 |
2006年 | 7916篇 |
2005年 | 7169篇 |
2004年 | 5764篇 |
2003年 | 5330篇 |
2002年 | 4657篇 |
2001年 | 4386篇 |
2000年 | 4364篇 |
1999年 | 3953篇 |
1998年 | 3872篇 |
1997年 | 3143篇 |
1996年 | 2802篇 |
1995年 | 3109篇 |
1994年 | 2900篇 |
1993年 | 2289篇 |
1992年 | 1832篇 |
1991年 | 1800篇 |
1990年 | 1451篇 |
1989年 | 1208篇 |
1988年 | 1200篇 |
1987年 | 1124篇 |
1985年 | 5574篇 |
1984年 | 7386篇 |
1983年 | 5906篇 |
1982年 | 6353篇 |
1981年 | 5796篇 |
1980年 | 4954篇 |
1979年 | 5016篇 |
1978年 | 4104篇 |
1977年 | 3082篇 |
1976年 | 3563篇 |
1975年 | 2752篇 |
1974年 | 2530篇 |
1973年 | 2237篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
3.
内生菌由细菌、真菌、古菌和原生生物组成,它们生活在植物的活体组织中,具有丰富的次级代谢产物多样性。人参内生菌在人参的生长发育、次级代谢产物的生成和环境适应等方面均有重要的促进作用,对人参的产量和品质有较大影响。随着人们在微生物领域研究的深入,高通量测序技术已经成为研究植物内生菌的重要方法。文章主要从人参内生菌分离与鉴定研究方法、人参内生菌的多样性、人参内生菌及其次级代谢产物的活性、人参内生菌对宿主的影响等4个方面对人参内生菌近年来的研究进展进行讨论,并对其发展方向提出展望,以期为药用植物内生菌研究和品质改良提供新思路、新方法。 相似文献
4.
A 25-year-old, emaciated man without medical treatment was found to have died suddenly at home by his mother. At autopsy, there were no injuries to his body, but significant circulatory insufficiency was observed. Electron microscopy revealed abnormal mitochondria in cells of the cardiac conduction system. The conduction system was filled with mitochondrial size abnormalities and mitochondrial cristae abnormalities. No notable abnormal findings were observed in other organs. Genetic examination of the blood revealed the mitochondrial pathogenetic variant m.3243A>G. Epileptic seizures, diabetic ketoacidosis, and hyperosmolar hyperglycemic state were unlikely to be the cause of sudden death. The cause of death was diagnosed as arrhythmia possibly induced by the failure of the cardiac conduction system due to mitochondrial disease. This is a rare case of sudden death caused by an accumulation of abnormal mitochondria in the cardiac conduction system. 相似文献
5.
目的 探讨糖尿病合并结核潜伏感染的研究现状、热点与前沿。方法 收集Web of Science核心合集于2000年1月1日至2021年11月20日发表的糖尿病合并结核潜伏感染的相关文章,运用CiteSpace 5.8.R3软件进行可视化分析。结果 共纳入英文文献148篇,近20年来该领域发文量呈上升趋势。美国发文量最多(46篇, 31.08%),机构间合作情况的可视化分析共得到个340节点、929条连线,网络密度为0.0161,作者间合作关系的知识图谱共得到790个节点、2425条连线,网络密度为0.0078,关键词共现分析结果显示,糖尿病合并结核潜伏感染的危险因素、患病率、诊断和治疗是该领域的研究热点和趋势。结论 糖尿病合并结核潜伏感染的发文量不断增加,机构间、区域内和国际范围内的合作有待进一步开展。立足国情,探索慢病共病的管理模式将有助于优化共病管理,进一步推动慢病管理的进程。 相似文献
6.
7.
《Archivos de bronconeumología》2022,58(1):11-21
BackgroundWe aimed to describe the effectiveness and safety of inhaled antibiotics in chronic obstructive pulmonary disease (COPD) patients, as well as the patient profile in which they are usually prescribed and the patient groups that can most benefit from this treatment.MethodsMulticentre retrospective observational cohort study in COPD patients who had received ≥1 dose of inhaled antibiotics in the last 5 years. Clinical data from the two years prior to and subsequent to the start of the treatment were compared. Primary outcome: COPD exacerbations. Secondary outcomes: side effects, symptomatology (sputum purulence, dyspnoea), microbiological profile and pathogen eradication.ResultsOf 693 COPD patients analyzed (aged 74.1; 86.3% men; mean FEV1 = 43.7%), 71.7% had bronchiectasis and 46.6% presented chronic bronchial infection (CBI) by Pseudomonas aeruginosa (PA). After 1 year of treatment with inhaled antibiotics, there was a significant decrease in the number of exacerbations (?33.3%; P < .001), hospital admissions (?33.3%; P < .001) and hospitalization days (?26.2%; P = .003). We found no difference in effectiveness between patients with or without associated bronchiectasis. Positive patient outcomes were more pronounced in PA-eradicated patients. We found a significant reduction in daily expectoration (?33.1%; P = .024), mucopurulent/purulent sputum (?53.9%; P < .001), isolation of any potentially pathogenic microorganisms (PPM) (?16.7%; P < .001), CBI by any PPM (?37.4%; P < .001) and CBI by PA (?49.8%; P < .001). CBI by any PPM and ≥three previous exacerbations were associated with a better treatment response. 25.4% of patients presented non-severe side-effects, the most frequent of these being bronchospasm (10.5%), dyspnoea (8.8%) and cough (1.7%).ConclusionsIn COPD patients with multiple exacerbations and/or CBI by any PPM (especially PA), inhaled antibiotics appear to be an effective and safe treatment, regardless of the presence of bronchiectasis. 相似文献
8.
9.
We present the case of a male patient with severe SARS-CoV-2 pneumonia, with simultaneous onset of p-ANCA positive rapidly progressive glomerulonephritis. We discuss the different therapeutic possibilities, emphasising the appropriateness of their administration according to the time in the course of the infection. 相似文献
10.